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ABSTRACT Outpatient parenteral antimicrobial therapy (OPAT) is a safe, effective,
and convenient treatment strategy for patients receiving intravenous antimicrobials
in the outpatient setting; however, data are limited describing the use and safety of
liposomal amphotericin B (L-AMB). Records of patients receiving L-AMB OPAT
between 1/1/2015 and 7/31/2018 were retrospectively reviewed. The primary objec-
tive was to describe the OPAT patient population discharged on L-AMB and evaluate
factors associated with readmission and adverse events (AEs). Analysis was per-
formed to evaluate for predictors of worse outcomes. Forty-two patients (67% male,
median age 50 years) were identified, most of whom were treated for histoplasmosis.
The most common doses of L-AMB were 3mg/kg (n=16, 38%) or 5mg/kg (n=14,
33%) based on actual body weight. Twenty-six (62%) patients completed their antici-
pated course of L-AMB. Twenty-two (52%) patients were readmitted within 30 days
of discharge; median time to readmission was 11 days (interquartile range [IQR] 5 to
18). While hypokalemia and acute kidney injury (AKI) were common, occurring in 26
(62%) and 20 (48%) patients, respectively, only 5 (12%) were readmitted to the hos-
pital due to L-AMB-associated AEs. Ninety percent of patients achieved at least par-
tial renal recovery within 30 days after L-AMB discontinuation. Factors significantly
associated with AKI include higher L-AMB dose, lower serum potassium levels after
therapy initiation, and receipt of potassium supplementation at discharge. L-AMB is
associated with significant AEs; however, these results suggest that treatment is fea-
sible in the outpatient setting with close monitoring, as the majority of AEs were
managed effectively in an outpatient without long-term sequelae.
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Outpatient parenteral antimicrobial therapy (OPAT) allows outpatient continuationof intravenous (IV) antimicrobials, reducing hospital length of stay and health
care-associated costs while increasing patient satisfaction (1–3). However, OPAT is not
without risks and complications. Decreased provider supervision increases risk of unde-
tected and untreated adverse events (AEs). Additionally, implementation of OPAT pro-
grams assisting in transitions of care and monitoring is low (4–6).
Available OPAT data primarily report antibiotic outcomes, but information is lacking
regarding amphotericin B (AMB) for invasive fungal infections (IFIs) treatment. Patients
with IFIs are often complex with significant comorbidities, like immune deficiency,
malignancy, and transplant recipients, and frequently require prolonged durations of
therapy (7–9). AMB remains the broadest spectrum systemic antifungal since its 1950s
introduction and is often the most effective agent for many IFIs (9, 10). However, ther-
apy is frequently limited by toxicity, including infusion reactions, electrolyte aberra-
tions, and nephrotoxicity (10). Lipid formulations, now mainstays of therapy, are associ-
ated with less toxicity than that of conventional deoxycholate (11). Liposomal
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amphotericin B (L-AMB) is the most widely used lipid formulation, but toxicity persists
despite routine intensive monitoring, adding to the complexity of managing patients
in less-supervised settings (11–16).
In the literature, AMB OPAT use is infrequent, ranging from 1 to 2% (2, 4, 12, 17–22).
Additionally, these studies include various AMB products for both prophylactic and
therapeutic indications. This study seeks to define patient populations receiving L-AMB
OPAT for IFI treatment and determine rates and factors associated with readmission
and AEs.
RESULTS
Forty-two patients received L-AMB OPAT between 01/01/2015 and 07/31/2018.
Median age was 50 years (IQR 37 to 62) and 28 (67%) were male. The most common
comorbidities were malignancy, receipt of immunosuppressive agents, diabetes melli-
tus, and receipt of stem cell transplant, in 19 (45%), 9 (21%), 6 (14%), and 6 (14%)
patients, respectively. Histoplasmosis was the most common indication (13 [31%]), fol-
lowed by aspergillosis (7 [26%]) and cryptococcosis (6 [14%]) (Table 1). Thirty-nine
patients (93%) initiated therapy during hospital admission, with median length of stay
of 9 days (IQR 5 to 22) (Table 2), while three (7%) started as outpatients. Most, 35
(83%), were managed with home infusion pharmacy and nursing services, four at
TABLE 1 Baseline and clinical characteristicsa
Characteristic
Median (IQR) or
n (%) (N= 42)
Age 50 (37–62)
Sex (Male) 28 (67)
Comorbidities
Malignancy 19 (45)
Solid tumor malignancy 3 (7)
Hematologic malignancy 16 (28)
Chemotherapy 15 (36)
Immunosuppressive medications (steroids, biologics, DMARDs) 9 (21)
Diabetes mellitus 6 (14)
Stem cell transplant recipients 6 (14)
Solid organ transplant recipients 1 (2)




Central nervous system 6 (14)






Urinary tract 1 (2)
Type of fungal infection
Histoplasmosis 13 (31)





Others: Fusarium, Irpex lacteus, Rhodoturula, Ustilago, and possible
dematiaceous fungus
5 (12) (one patient [2%]
in each category)
aIQR, interquartile range; DMARDs, disease modifying anti-rheumatoid drugs; HIV, human immunodeficiency
virus.
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TABLE 2 Therapy characteristics and outcomesa
Therapy characteristic or outcome
Median (IQR) or
n (%) (N= 42)
Liposomal amphotericin B dose, mg/kg 4 (3–5)






Index hospitalization length of stay (39 patients), daysb 9 (5–22)
Hypokalemia during index admissionb 25 (64)
Significant hypokalemia during index admissionb 13 (33)
Nadir potassium during index admissionb 3.1 (2.8–3.5)
Serum creatinine at discharge, mg/dl 0.9 (0.7–1.1)
Serum potassium value at discharge, mmol/liter 3.8 (3.5–3.9)
Serummagnesium value at discharge, mg/dl 1.9 (1.7–2)




Infusion center 2 (7)
OPAT clinical course
Duration
Planned length, days 28 (14–42)
Actual total duration, including inpatient and outpatient (40 patients), days 26 (14–37)
Outpatient duration of therapy, days 14 (10–26)
Completion of L-AMB course fully as an outpatient 23 (55)
Median duration of therapy for those completing full course as an
outpatient, days
18 (14–30)
Monitoring laboratory frequency, times per wk 2 (1–2.5)
Renal toxicityc
Acute kidney injury 20 (48)
Maximum serum creatinine after discharge, mg/dl 1.29 (1–1.59)
Time to acute kidney injury, days 8.5 (5–14)
Patients received concomitant intravenous hydration with L-AMB 21 (50)
Electrolyte managementc
Hypokalemia (K, 3.5mmol/liter) after discharge 26 (62)
Severe hypokalemia (K, 3.0mmol/liter) after discharge 16 (38)
Potassium supplement prescribed at discharge 22 (52)
Nadir potassium after discharge, mmol/liter 3.1 (2.8–3.7)
Time to nadir hypokalemia, days 7 (4–9)
Magnesium supplement prescribed at discharge 12 (29)
Nadir magnesium after discharge, meq/liter 1.6 (1.5–1.9)
Readmission
30-day hospital readmission 22 (52)
Time to readmission, days 11 (5–18)
Reason for 30-day hospital readmission (N= 22 [52%])
Adverse drug reaction 5 (12)
Acute kidney injury 3
Hypokalemia 2
Worsening of infection 3 (7)
Other reasons, e.g., graft versus host disease, stem cell transplant,
Clostridioides difficile infection, bacterial sepsis
14 (33)
aIQR, interquartile range; L-AMB, liposomal amphotericin B; ID, infectious diseases; OPAT, outpatient parenteral
antimicrobial therapy; SNF, skilled nursing facility; LTAC, long-term acute care facility.
bAnalysis included only those who were started during a hospitalization and did not include three patients
started as an outpatient.
cWhen scored on the Naranjo scale, all cases met at least probable criteria due to temporal sequence, recognized
AEs, and improvement upon withdrawal (32).
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postacute care facilities (PACFs), and two at infusion centers (Table 2). Labs were drawn
a median of twice weekly (IQR 1 to 2.5). The most common L-AMB daily doses were 3
and 5mg/kg, 16 (38%) and 14 (33%), respectively. Median total duration of therapy
(inpatient and outpatient) was 26 days (IQR 14 to 37), and median OPAT duration was
14 days (IQR 10 to 26), resulting in 1,042 total OPAT days.
Twenty-two patients (52%) were readmitted within 30 days, occurring at a median
of 11 days (IQR 5 to 18) (Table 2). Five patients (12%) were readmitted due to L-AMB-
associated AEs (two for hypokalemia [serum potassium {K} 1.9 and 2.4mmol/liter] and
three for AKI) and three (7%) were readmitted due to worsening of IFI. Remaining read-
missions, 14 (33%), were due to factors unrelated to L-AMB or IFI. No factors were sig-
nificantly associated with readmission; however, readmissions were numerically higher
in patients with malignancy (13/22 [59%] versus 6/20 [30%], odds ratio [OR] 3.37, 95%
confidence interval [CI] 0.94 to 12.11).
Mortality occurred in two patients, both of whom developed AKI during therapy,
due to progression of fungal disease (disseminated mold infection and resistant
Candida glabrata candidemia).
Twenty-six (62%) patients completed their anticipated L-AMB duration (Fig. 1). This
included patients who were readmitted but for whom L-AMB continued as planned.
Twenty-three (55%) completed L-AMB as outpatients, with a median duration of
18 days (IQR 14 to 30 days) (Table 2). L-AMB was held in nine patients (21%) for AE
management but was resumed and courses were completed successfully. Of those
with early L-AMB discontinuation, 88% switched to an azole antifungal. Four patients
experienced infusion reactions, two with rigors or chills and one each with fever and
anaphylaxis.
Upon L-AMB OPAT initiation, median serum creatinine (SCr) was 0.9mg/dl (IQR
0.7 to 1.1); however, 20 patients (48%) developed AKI at a median of 8.5 days (IQR 5
to 14). This occurred despite 50% (n= 21) receiving concurrent IV hydration. Factors
associated with AKI (Table 3) included lower inpatient serum potassium after L-AMB
initiation (3 versus 3.3mmol/liter, P = 0.04), discharge prescription of potassium sup-
plementation (70% versus 36%, OR 4.1, 95% CI 1.1 to 14.9), and higher L-AMB dose
(4.6 versus 3.2mg/kg, P = 0.05). Intravenous hydration was not associated with lower
AKI risk (45% versus 55%, OR 0.7, CI 0.2 to 2.3). No patients with AKI developed hy-
perkalemia, and median outpatient maximum potassium was 4.3mmol/liter (IQR 2.9
to 5).
Of those who developed AKI, five (25%) achieved full renal recovery within
30 days after discontinuation, while all surviving patients, 18 (90%), experienced at
least partial recovery. At 1 year postdiscontinuation, 13 (65%) experienced full renal
recovery at a median of 54 days (range 30 to 309). AKI management was
FIG 1 Outcomes of liposomal amphotericin B OPAT therapy.
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determined based on clinical judgment, resulting in 7 (35%) conversions to azole
antifungals; however, 13 continued L-AMB. Seven (35%) were monitored and did
not require therapy adjustment, 3 (15%) adjusted frequency to 48 h, and 1 (5%)
adjusted frequency to thrice weekly. No patient required hemodialysis due to
L-AMB nephrotoxicity.
Potassium was within normal limits for over 75% of patients upon initiation of
L-AMB OPAT; however, despite supplementation in 22 (52%), 26 (62%) developed hy-
pokalemia, median nadir of 3.1mmol/liter (IQR 2.8 to 3.7). Sixteen (38%) developed
severe hypokalemia, associated with age (40 versus 59 years, P = 0.05), L-AMB dura-
tions (30 versus 19.5 days, P = 0.02), and nadir magnesium (1.5 versus 1.7 meq/liter,
P= 0.04).
DISCUSSION
To date, few reports detail L-AMB OPAT experiences (12, 21–23). This is the largest
description of adult L-AMB OPAT patients, most of whom received daily infusions. We
sought to determine rates and reasons for readmission and AEs to better understand
this patient population and provide a description of L-AMB OPAT.
As expected with this complex population, readmission rates were high, occurring
in 22 (52%) patients. However, most readmissions were unrelated to L-AMB, 14
(33%), with only 5 (12%) due to L-AMB-associated AEs (3 AKI and 2 hypokalemia).
No factors were significantly associated with readmission; however, patients with
malignancy were more frequently readmitted. L-AMB-associated readmission rates
are similar to those from a previous study of outpatient amphotericin (12%); how-
ever, nonlipid AMB formulations were included in that study (12). In a study reporting
thrice-weekly L-AMB OPAT, readmissions occurred in 22%, but only one (6%) read-
mission was attributed to L-AMB AKI (21). L-AMB-associated readmissions occurred in
17% (2/12) of patients in a study of antifungal OPAT that also utilized thrice-weekly
administration (22).
High AE rates (20 to 72%) associated with lipid formulations are most notably due
to AKI, varying between 9 and 25%, and electrolyte abnormalities (12–14). Compared
to those in AMB deoxycholate, incidences of nephrotoxicity and infusion reactions are
TABLE 3 Factors associated with acute kidney injury (bivariate analysis)a
Variable
Acute kidney injury
median (IQR) or n (%)
(N =20 [48%])
No acute kidney injury
median (IQR) or n (%)






Age, yrs 56 (37–63) 48 (37–59) 0.80
Sex, male 11 (55) 17 (77) 0.19 0.4 0.1–1.4
Diabetes mellitus 4 (20) 2 (9) 0.40 2.5 0.4–15.4
L-AMB dose, mg/kg 4.6 (3.3–5.1) 3.2 (3–4.4) 0.05
Index hospitalization length of stay, days 9 (7–18) 10 (5–24) 0.65
Frequency of laboratory monitoring, times per wk 2 (1–3) 2 (1–2) 0.34 1.3 0.6–2.5
Duration of therapy of L-AMB therapy, days 27.5 (14.5–35) 26 (14–43) 0.91
Patient received concomitant IV hydration 9 (45) 12 (55) 0.54 0.7 0.2–2.3
Concomitant nephrotoxic agent 6 (30) 2 (9) 0.12 4.3 0.8–24.4
Serum creatinine at hospital discharge, mg/dl 0.9 (0.7–1.2) 0.87 (0.7–1) 0.45
Peak serum creatinine, mg/dl 1.6 (1.4–1.8) 1 (0.9–1.2) NA NA
Serum potassium at hospital discharge, mmol/liter 3.8 (3.5–3.9) 3.8 (3.5–3.9) .0.99
Potassium supplementation prescribed at discharge 14 (70) 8 (36) 0.03 4.1 1.1–14.9
Nadir potassium after discharge, mmol/liter 3.2 (2.9–3.8) 3.1 (2.7–3.6) 0.53
Hypokalemia (K, 3.5mmol/liter) during index hospitalization 14 (78) 10 (48) 0.10 3.9 0.9–15.7
Significant hypokalemia (K, 3.0mmol/liter) during index
hospitalization
8 (44) 4 (19) 0.16 3.4 0.8–14.2
Nadir potassium level during index hospitalization 3 (2.7–3.2) 3.3 (3.1–3.8) 0.04
Serummagnesium at hospital discharge, mg/dl 1.8 (1.6–1.9) 1.9 (1.8–2) 0.08
Magnesium supplementation prescribed at discharge 7 (35) 5 (23) 0.50 1.8 0.5–7.1
Nadir magnesium after discharge, mg/dl 1.6 (1.3–1.7) 1.8 (1.6–2) 0.06
aIQR, interquartile range; ID, infectious diseases; IV, intravenous; L-AMB, liposomal amphotericin B; NA, not applicable.
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lower with L-AMB and other lipid formulations (14, 24). Previous data suggest that
there may not be a strong association with AEs and L-AMB dose; however, we noted
an association with increased L-AMB dose and AKI (24–26). Most data regarding L-
AMB-associated AEs describe inpatients, but in one study evaluating outpatient AMB,
nephrotoxicity occurred in 50% of adults (12).
Conflicting nephrotoxicity definitions are present in AMB literature. These ranged
from our definition, 0.5mg/dl or 50% increase from baseline SCr, to $1mg/dl increase
or doubling of baseline SCr (11, 12, 14, 21, 24). As such, rates range from 10 to 56%
depending on definitions used (11, 12, 14, 21, 24). A more conservative definition was
used in this study, reflecting clinical practice of our OPAT program.
Sodium loading has reduced nephrotoxicity in hospitalized patients receiving AMB
deoxycholate (12, 27, 28). Half of our patients received sodium loading via IV hydration
with normal saline pre- and postinfusion upon OPAT initiation; however, this rose to
31 (74%) after intervention by the OPAT team. This is consistent with sodium loading
practices reported in a survey of inpatient clinical pharmacists regarding prophylactic
strategies to prevent AMB lipid formulation AEs, in which 68% reported routine use of
IV fluid boluses (29), and similar to a previous report of community-based AMB, in
which 50% received sodium loading (12). Unlike AMB deoxycholate, a trend toward
lower nephrotoxicity was not seen in patients who received sodium loading, and it is
unclear whether this benefit exists for L-AMB, as studies have not assessed effect on
lipid formulations. Conversely, excessive fluid loading may play a role in exacerbating
potassium wasting in the setting of magnesium deficiency (30).
Previous studies reporting AMB OPAT found that high rates of nephrotoxicity occurred
in older patients, those who had received a solid organ transplant, and those who were
receiving concomitant cyclosporine (12). We observed an association with lower inpatient
potassium levels and potassium supplementation on discharge. It is possible that hypoka-
lemia is an early sign of L-AMB-induced nephrotoxicity. Magnesium deficiency may exacer-
bate hypokalemia and render it refractory to treatment by potassium replacement (30). As
such, patients with magnesium deficiency may be unable to replete potassium stores with
potassium supplementation alone.
While AKI occurred frequently, no patient required hemodialysis. Patients achieved
full renal recovery after discontinuation up to a rate of 65%, with 25% recovering
within 30 days, similar to the results in prior reports (31). However, it should be noted
for those with incomplete renal recovery that there may be implications affecting
future therapy choices for underlying disease, emphasizing that L-AMB is not benign.
While two patients died and experienced worsening renal function while on L-AMB,
mortality was attributed to worsening infection. Inpatient management for patients at
high risk for complications and those indicated for shorter courses may provide an op-
portunity for closer monitoring, allowing for earlier AE detection.
AEs were common, requiring close supervision by the OPAT team, which allowed
for attentive and frequent laboratory monitoring, timely electrolyte replacement, and
therapy adjustments. Over the last decade, OPAT team utilization has expanded, allow-
ing for more comprehensive outpatient management. In a 2018 infectious diseases
(ID) physician survey, 36% reported OPAT program utilization, up from 26% in 2012 (5,
6). Despite increased OPAT programs, significant barriers to care still exist.
IDSA’s 2018 Clinical Practice Guidelines for the Management of OPAT recommends
at least twice-weekly monitoring of potassium and SCr and weekly liver function tests
(LFT) and complete blood counts (CBC) for L-AMB (1). In a survey of OPAT practices
among adult ID physicians, 415/450 responded regarding L-AMB monitoring fre-
quency; 47% reported twice-weekly monitoring, followed by once- (24%) and thrice-
weekly (22%) monitoring (5). The Washington University School of Medicine (WUSM)
ID OPAT team provides recommendations for thrice-weekly basic metabolic panels
and once-weekly CBC and LFTs, guiding providers ordering laboratory studies on dis-
charge. Despite this recommendation, we found that patients most often received
twice-weekly studies (IQR 1 to 2.5). Patients with severe hypokalemia received more
Burnett et al. Antimicrobial Agents and Chemotherapy















































frequent monitoring, likely due to increased monitoring after supplementation and
trending potassium losses. High-frequency monitoring may not be feasible for all situa-
tions, but we agree with at least twice-weekly laboratory monitoring.
Barriers to OPAT transitions of care include appropriate discharge ordering of labo-
ratory studies, access to outpatient laboratory data, and communication between
OPAT teams and patients or PACF (6). First-hand experience in management of this
population reveals that while barriers may be overcome by a dedicated and efficient
OPAT team, significant manpower is necessary to address these issues. Additionally,
clear and efficient communication among team members and patients is paramount,
due to frequent therapy adjustments to mitigate AEs. Appropriate patient selection, of
stable patients in whom prolonged hospitalization may be detrimental, also aids in
successful OPAT courses. Developing action plans in anticipation of AEs, such as
thresholds for therapy adjustments or electrolyte replacement, allows for quick action
from the OPAT team and decreases time to intervention. In review of these data, reduc-
tion in L-AMB frequency may be an effective management strategy given L-AMB’s long
half-life, as seen in a few recent reports (21–23).
Limitations are those inherent to retrospective studies, as data were collected from
chart review and limited to provider documentation. While numbers were small, given
the rarity of L-AMB OPAT, it is a relatively large study. The small sample size limits abil-
ities to assess readmission and AE contributing factors, though some associations may
be helpful when caring for this challenging patient population.
Strength of this study lies in examination of L-AMB OPAT in the current era of more
prevalent OPAT programs. Few studies have evaluated outpatient AMB and included
prolonged study periods (5 to 10 years) and multiple AMB formulations. This study is
unique, as prophylactic dosing was excluded. Patients received higher and more frequent
dosing than those on prophylaxis, allowing for inclusion of a population more likely to ex-
perience AEs. In addition, all patients in this study received L-AMB, while previous studies
report on mixed use of AMB deoxycholate and lipid formulations (12, 18–20). This study
provided real-life experience with L-AMB OPAT, reporting clinically relevant outcomes,
including readmission, significant hypokalemia, AKI, and associated factors.
Treatment with L-AMB OPAT is feasible but not without risks. With close monitoring
and early intervention, OPAT teams can effectively manage a majority of L-AMB-associ-
ated AEs, without readmission or long-term sequelae. As OPAT programs continue to
expand, additional work is needed to mitigate barriers to effective OPAT care, such as
laboratory data access, correct discharge laboratory monitoring orders, and detecting
transitions of care errors in these high-risk patients.
MATERIALS ANDMETHODS
This retrospective cohort consists of patients of $18 years who were managed by Washington
University School of Medicine (WUSM) in St. Louis, Division of Infectious Diseases (ID) OPAT team
receiving outpatient L-AMB from 01/01/2015 to 07/31/2018. Only L-AMB treatments prescribed for
therapeutic purposes were included, excluding lower prophylactic doses. The WUSM ID OPAT team,
consisting of an ID physician and pharmacist, midlevel providers, and nurses, coordinates transitions of
care, monitors laboratory results (at minimum once weekly), and cares for .1,500 patients annually.
Patients were identified utilizing the OPAT database maintained by clinic nurses and ID pharmacist.
Patients are referred to the OPAT team via ID consult during hospitalization at Barnes-Jewish Hospital,
a 1,368-bed academic medical center, or outpatient referral. Patients received L-AMB at home with
home infusion pharmacy and nursing, at postacute care facilities (PACF), or at outpatient infusion
centers.
Data points were abstracted from the electronic medical record utilizing a standardized data collec-
tion form by two abstractors and included patient demographics, comorbidities, concomitant medica-
tions, laboratory data, IFI indication, L-AMB dosage, electrolyte supplementation, IV hydration, 30-day
hospital readmission data, and reported AEs. Discrepancies were resolved by discussion with study
investigators (Y. J. Burnett, Y. Hamad). Data were managed using REDCap (Research Electronic Data
Capture), a secure, web-based application hosted by Washington University School of Medicine Institute
for Informatics, Informatics Core Services. Deidentified data were downloaded and stored via a secure
server for statistical analysis. The study was approved by the Human Research Protection Office at
Washington University in St. Louis.
Study definitions include the following. Acute kidney injury (AKI): 0.5mg/dl or 50% increase from
baseline serum creatinine (SCr). Full renal recovery: return to 50% of baseline SCr at 30 days and 1 year
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after L-AMB discontinuation. Partial renal recovery: decrease by one stage of chronic kidney disease.
Hypokalemia: K, 3.5mmol/liter. Severe hypokalemia: K, 3.0mmol/liter. Hypomagnesemia: Mg, 1.5
meq/liter. Infusion reactions: chills, fever, nausea, vomiting, dyspnea, chest pain, hypotension, and mus-
cle spasm during or immediately following L-AMB infusion. AEs were classified in accordance with the
Naranjo adverse drug reaction probability scale (32). Indication and planned duration of therapy were
obtained from the ID provider note. For indefinite or long-term planned durations, 90 days was used as
an estimate of how long patients may tolerate therapy.
Descriptive statistics analyzed baseline characteristics, care-related measures, and readmissions. Chi-
square test analyzed categorical values, while Wilcoxon rank sum was used for continuous values. Odds
ratios and 95% confidence intervals were calculated for categorical variables. Missing values were elimi-
nated from analysis.
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